Cyclerion Therapeutics In... (CYCN)
Company Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.
Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS.
It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Country | United States |
IPO Date | Mar 18, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Dr. Regina M. Graul Ph.D. |
Contact Details
Address: 245 First Street Cambridge, Massachusetts United States | |
Website | https://www.cyclerion.com |
Stock Details
Ticker Symbol | CYCN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001755237 |
CUSIP Number | 23255M105 |
ISIN Number | US23255M2044 |
Employer ID | 83-1895370 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Regina M. Graul Ph.D. | Chief Executive Officer, President & Director |
Rhonda M. Chicko CPA | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 07, 2025 | 8-K | Current Report |
May 07, 2025 | 424B5 | Filing |
May 06, 2025 | S-3 | Filing |
May 06, 2025 | 10-Q | Quarterly Report |
Apr 29, 2025 | DEFA14A | Filing |
Apr 29, 2025 | DEF 14A | Filing |
Mar 28, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 27, 2025 | 4 | Filing |
Mar 27, 2025 | 4 | Filing |